EBSCO Information Services 2013 June Don t Rush To Crush

Similar documents
Good Practice Guidance on Covert Administration of Medication

Oral Systemic Therapy

Quality Use of Medicines in Children

247 CMR BOARD OF REGISTRATION IN PHARMACY

Student Guide to EHR Go

MATERIAL SAFETY DATA SHEET

Sorafenib (Nexavar ) ( sor-af-e-nib )

Oral Systemic Therapy

A themed review of patient safety incidents involving anti-cancer medicines 1 November June 2008

Medication and Dysphagia To crush or not to crush? Paresh Parmar Care of Elderly & Stroke Pharmacist Northwick Park Hospital

North of England Cancer Network. Policies and Procedures. Standards for the Safe Use of Oral Anticancer Medicines

Medicines to treat pain in adults. Information for patients and carers

Version: 3.0 Head of Chemotherapy (HoC)/ Lead cancer clinician (LCC) / Lead cancer nurse (LCN) Reviewed by Chemo Working Group April 2016

Information Sheet 10. Medication Hints and Tips (Updated August 2014)

Chapter 8: ICD-10 Enhancements in Avalon

Eltrombopag (Promacta )

Welcome to your. Pharmacy Services Guide. Many of our stores are open 24 hours. To find one near you, visit or call SHOP CVS.

MATERIAL SAFETY DATA SHEET

Medicines Q&As Q&A What are the therapeutic options for patients unable to take solid oral dosage forms?

Everolimus (Afinitor )

healthdirect Symptom Checker Communications Toolkit

Principals and dosage forms of pharmaceutics

Preparation of TAMIFLU for Oral Suspension. Emergency Compounding of an Oral Suspension from TAMIFLU Capsules (Final Concentration 15 mg/ml)

Drug Information Sheet("Kusuri-no-Shiori")

MATERIAL SAFETY DATA SHEET

MATERIAL SAFETY DATA SHEET

ADVANCE PREPARATION OF INSULIN FOR PATIENTS TO ADMINISTER AT HOME

MATERIAL SAFETY DATA SHEET

Dealing with Uninvited Guests: Excipients. Mark Klang, MS, RPh, PhD, BSNSP Research Pharmacy Manager Memorial Sloan Kettering Cancer Center

Medication Safety Presentation

NOTE: The first appearance of terms in bold in the body of this document (except titles) are defined terms please refer to the Definitions section.

Disclosure. Objectives. Objectives. Introduction. Introduction. Non-Sterile Compounding/Calculations

Tacrolimus. Information for Parents/Carers

Compounding KI for Radiation Exposure

Unit 204 Assist with the assembly of prescribed items

MATERIAL SAFETY DATA SHEET

Dabrafenib (Tafinlar )

Guidelines for acute treatment of patients with Parkinson s disease including those who are nil by mouth

Lenvatinib (Lenvima ) ( len-va-ti-nib )

Introduction to the Globally Harmonized System of Classification and Labeling of Chemicals. GHS Training Module 1

Strategies for Managing Your Medications

MATERIAL SAFETY DATA SHEET

MATERIAL SAFETY DATA SHEET

Material Safety Data Sheet Product Name: LAWRIE CO STOCK LICK SKINS. Web: HAZARD IDENTIFICATION

innovative products. faster to market. reliably supplied.

Appendix 3 Administration of Covert Medication Review Form

Industry Perspective on Formulation and Packaging Considerations

This safety data sheet conforms to Regulation (EC) No. 1272/2008. Version

Guidance on Bulk Prescribing for Care Home Patients

Tube feeding with a nasogastric or nasojejunal tube

The Pharmacy Board of Australia s

NHS Grampian Protocol For The Prescribing And Administration Of Oral Opioids Following Trauma Or Surgery in Adults. Consultation Group: See Page 5

Taking the guesswork out of supplying multi-compartment compliance aids: do pharmacists

Memantine pronounced as (mem' an teen)

Switching to Enterprise Drugs

Product Characteristics and Product Information Links between Quality and Clinical

Midostaurin (Rydapt )

NHS Grampian Protocol For The Prescribing And Administration Of Oral Opioids Following Trauma Or Surgery

Tube Feeding Using the Gravity Method

User Manual. RaySafe i2 dose viewer

MATERIAL SAFETY DATA SHEET

Care homes - Homely remedies

Imatinib (Gleevec ) ( eye-mat-eh-nib )

MATERIAL SAFETY DATA SHEET

Guide to using your Medicine Safely

PACKAGE LEAFLET: INFORMATION FOR THE USER. BritLofex Tablets 0.2mg LOFEXIDINE HYDROCHLORIDE

Tremendous Diagnostic Imaging Spine 3e

MOATT Card-Style Version: A single page MOATT (PDF) is also available at the MASCC website.

LIQUID PREPARATIONS FOR ORAL USE. Final text for addition to The International Pharmacopoeia (November 2007)

Instructor Guide to EHR Go

KOMBAT RATS & MICE BLOCKS Registration No. L6425, ACT 36 OF 1947

Ibrutinib (Imbruvica )

Bioequivalence of Oral Generic Product with An Alternate Administration

Neuro-Medivitan is a vitamin preparation. Intended use Systemic neurological disorders due to proven deficiency of vitamins B1 and B6.

The Pharmaceutical and Chemical Journal, 2016, 3(2): Research Article

A Framework for Optimal Cancer Care Pathways in Practice

1. Identification of the substance/mixture and of the company/undertaking Zuchwil / Schweiz

Patient and Public Reference Group for Medicines ADTC Sub-group NHS Tayside 17 th February 2015

Printing Date 07/24/2009 Page 1 of 7 Product Name: Paul Mitchell Flash Back Medium Warm Natural (6WN) Material Safety Data Sheet acc.

NZ Organised Stroke Rehabilitation Service Specifications (in-patient and community)

Food supplement manufacture

REVISION OF MONOGRAPH ON TABLETS. Tablets

Tube Feeding With a Pump

Material Safety Data Sheet This MSDS is prepared in accordance with OSHA 29 CFR

THE FACTS ABOUT PRESCRIPTION MEDICINE MISUSE

CHEWABLE SOFTGEL TECHNOLOGY

MATERIAL SAFETY DATA SHEET

National Self Care Week Newsletter Second Edition

Medicines in Schedule 1 to the Medicine Regulations 1984 that reference the manufacturer s original pack

Clinical Evidence. A BMJ database of the very best evidence for effective health care

Please read this leaflet carefully before you start to use Vagifem and keep it with your medicine. You may need to read it again.

Start your patient s drug education

APO-Ondansetron Contains the active ingredient, ondansetron (as hydrochloride dihydrate)

SleepImage Website Instructions for Use

CHAPTER 3 Medicines 35

This letter is to notify you of recent changes to the TAMIFLU product monograph. Please note, additions/changes have been highlighted in yellow.

6/7/2017 CHANGES IN PHARMA REGULATIONS HOW IT AFFECTS THE OR NURSE DISCLOSURE OBJECTIVES

MATERIAL SAFETY DATA SHEET

Cambridgeshire Community Services NHS Trust: delivering excellence in children and young people s health services

Transcription:

EBSCO Information Services 2013 June 2013 Don t Rush To Crush MIMS Online now provides guidance to therapeutic options for people unable to take solid oral medicines. MIMS Online offers Don t Rush to Crush as an optional content module for CAUL libraries that provides Australia s most comprehensive guide to administering solid oral medicines to patients who are unable to swallow. The Don t Rush to Crush guidance is produced and maintained by The Society of Hospital Pharmacists of Australia (SHPA), the professional body which represents around 3,000 pharmacists, pharmacy technicians and associates practicing in all parts of the Australian health system.

Don t Rush To Crush Summary The foundation treatment for most medical conditions is the taking of medications. With the population aging medications will be the foremost aid in providing quality of life and longevity. The method of medicines administration will to some extent determine the gained therapeutic value; it may also determine whether any adverse effect is experienced. The administration of medicines is perhaps the most common clinical procedure that a nurse undertakes. However this task is often complicated when patients become non-compliant with their medication due to problems swallowing. This problem is frequent, swallowing difficulties are common with 60% of aged care residents and 40% of the general population finding it difficult to swallow their daily medications. When a tablet or capsule cannot be swallowed an obvious solution might be to crush the tablet or open the capsule and add the medication to food or drink. However many tablets and capsules are not designed to be crushed or opened. Changing the form of the medication may see it become toxic to the patient or reduce the safety or efficacy. For example, crushing an extended release drug can destroy the medication time release properties with the whole dose being released within a few minutes rather than the intended 12 or 24 hours. With the need for clear, professional advice regarding the suitability of crushing a medicine the Society of Hospital Pharmacists of Australia published Don t Rush to Crush which is now available as additional optional content within MIMS Online. 1

Intuitive and rapid access to information on the suitability of a medication to be crushed or dispersed The MIMS Online Don t Rush to Crush content provides monographs for over 500 Australian medicines listing generic names, brand names and available forms and strengths. There are separate recommendations for administering solid oral dose forms to patients with swallowing difficulties and patients with enteral feeding tubes. The information is delivered for appropriate medications in a tabbed window only one click away from the full product information, abbreviated information and consumer medicine information. The use of quick guide symbols in the Don t Rush to Crush monographs provides intuitive and rapid guidance and access to information of the suitability of a medication to be crushed or dispersed. In the case where a medication is unsuitable for crushing this is clearly indicated. Indicates a proprietary oral liquid Indicates a tablet, capsule or granules that may be dispersed Indicates a tablet or capsule contents that may be crushed using a mortar and pestle or tablet crushing device Indicates a tablet, capsule contents or granules that should not be crushed Indicates a medicine that may be hazardous and precautions should be taken if dispersing or crushing Indicates a medicine that is cytotoxic and special handling precautions are required The Don t Rush to Crush content delivered within MIMS Online ensures that advice needed for patients receive their medicines in a manner that is safe and maintains the efficacy of the medicine is always on hard at the point of care or medication preparation. The information provides assistance to all Australian health environments including hospitals, rehabilitation services, and clinics. 2

Quality information with a robust Editorial Process A multidisciplinary approach is important to achieving positive medication outcomes for consumers. To best meet this need the team producing the Don t Rush to Crush content includes health professionals and clinicians from a variety of disciplines including pharmacists, dietician, nurse and allied health professionals. A rigorous content review ensures that the guidance is evidence based and facilitates unbiased decision making according to current standards of care. The content is managed by a team of two Pharmacist Editors. The Editors are assisted by a Monograph Editorial Committee who are responsible for the content of the monographs, Introduction Subcommittee responsible for the additional guidance and content beyond the monographs, and a team of pharmacist monograph reviewers. In all, over forty five clinicians and health professionals review and maintain the content. The contributors are primarily members of the Society of Hospital Pharmacists currently practicing in the public health sector in Australia. Several pharmaceutical companies have also provided information included in individual drug monographs. This information has been provided on the understanding that these companies do not advocate the off-label use of products manufactured and produced by them. Information provided by these companies can be found in the monograph references as personal communication. FIG 2 - Example DRTC monograph for a medication UNSUITABLE for crushing 3

Integration of Don t Rush to Crush Content into MIMS Online Don t Rush to Crush content is seamlessly integrated into MIMS Online and is retrieved via the standard search methods that are used for navigating to product or consumer information. Searching for a product by brand name, generic or ingredient name, therapeutic class or action / indication will lead the user to a number of tabbed windows that display information about the medication. Typically in MIMS Online the available tabs are Abbreviated Product Information, Full Product Information and Consumer Medicines Information. When Don t Rush to Crush content is available an additional tab which contains the DRTC advice and guidance. This information is always only one mouse click away from the standard MIMS information, but remains clearly separated to avoid confusing the content with the official MIMS product information.. FIG 3 - Example DRTC Monograph for a medication SUITABLE for crushing 4

Typical Navigation of Don t Rush to Crush - Search The Don t Rush to Crush information is fully accessible within MIMS Online by following standard MIMS Online searching and information navigation flows. Searching for either a generic or branded medication will display a SHPA (Society of Hospital Pharmacists) link if Don t Rush to Crush content is available. In the example below the Diltiazem Hydrochloride has been entered in the MIMS Online Simple Search. The resulting display indicates relevant branded medications and the ability to view Don t Rush to Crush information with one single click.. FIG 4 - Example DRTC MIMS Online Simple Search 5

Don t Rush to Crush Monograph Display The Don t Rush to Crush monograph is displayed within a Tabbed Content Pane when the SHPA link is selected from any MIMS Online search result. To ensure the end-user does not confuse the medication crushing advice medication product information or the consumer medicines information sheet the Don t Rush to Crush content is separated into a dedicated tab pane. The monograph is identical to the relevant page displayed in the printed Don t Rush to Crush publication provided by the SHPA. Conveniently the associated product information and consumer information for the medication is only one mouse click away. FIG 4 - Example DRTC MIMS Online Monograph Display 6